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Purpose
Chronic lateral epicondylosis (CLE) is common, expen-
sive and debilitating. A substantial number of patients
are refractory to existing therapy and “watchful waiting.”
Prolotherapy is a CAM injection therapy for chronic
musculoskeletal pain including tendinopathy. We
assessed dextrose prolotherapy for CLE in a pilot-level
study.
Methods
The study design was a 2-arm non-blinded randomized
controlled trial. Group 1 received dextrose prolotherapy
and Group 2 was a waitlist control. Nineteen adults seen
with at least 3 months of symptomatic CLE in 22 elbows
refractory to prior care received ultrasound-guided injec-
tions of 20% dextrose-morrhuate sodium (Group 1) solu-
tion at baseline, 4, and 8 weeks. Waitlist subjects (Group 2)
were followed and discouraged from starting new care. Pri-
mary outcome measure was Patient-rated Tennis Elbow
Evaluation [PRTEE, (100 points) assessed at baseline, 4, 8
and 16 weeks]. Prolotherapy participants were additionally
assessed at 32 weeks. Secondary measures included dynam-
ometer-assessed pain free grip strength and participant
satisfaction.
Results
No baseline differences existed between the groups in
gender, duration of elbow pain, prior therapy or baseline
PRTEE scores. Prolotherapy participants (n=10) reported
improved PRTEE composite scores compared to Waitlist
(n=12) at 4 and 16 weeks (p<0.05), and improved pain
and function PRTEE subscale scores (p<0.05) at 4 and 16
weeks, respectively. Prolotherapy participants reported
improvement in composite PRTEE scores from baseline
at 16 and 32 weeks of 17.9±11.64 and 24.8±10.58 points,
a difference of 49.7% and 70.2% respectively, far in excess
of the 11-point PRTEE-based minimal clinical important
difference. Grip strength improved in all groups without
between-group difference. Satisfaction with prolotherapy
was high; there were no adverse events.
Conclusion
Prolotherapy using dextrose and morrhuate sodium
resulted in safe, significant, sustained improvement of
PRTEE-based elbow composite, pain and function scores
compared to baseline status and waitlist control sub-
jects. The results of this pilot study suggest the need for
a definitive clinical trial.
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